Biopharmaceutical company GSK plc (LSE:GSK) (NYSE:GSK) on Wednesday raised its guidance for the full year after reporting strong growth in the second quarter.

Turnover in the three months ended 30 June 2022 amounted to GBP6.9bn, up 19% or 13% at constant exchange rates.

Vaccine sales totalled GBP1.7bn, including a record quarter for the company's shingles vaccine Shingrix which generated GBP731m in sales.

Adjusted operating profit for the second quarter was GBP2.0bn, a year-on-year increase of 22% or 7% at constant exchange rates.

GSK now expects full-year sales to grow by 6% to 8% (previously 5% to 7%), with adjusted operating profit up 13% to 15% (previously 12% to 14%), excluding COVID-19 related revenues.

(USD1=GBP0.83)